Company Description
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States.
The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals.
Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025.
Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Hyunsu Jung |
Contact Details
Address: 295 Madison Avenue, Suite 2400 New York, New York 10017 United States | |
| Phone | 917 289 1117 |
| Website | hyperiondefi.com |
Stock Details
| Ticker Symbol | HYPD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682639 |
| CUSIP Number | 30234E104 |
| ISIN Number | US30234E2037 |
| Employer ID | 47-1178401 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hyunsu Jung | Chief Executive Officer, Chief Investment Officer and Director |
| David Knox C.F.A. | Chief Financial Officer |
| Norbert Lowe | Senior Vice President of Commercial Operations |
| Enrico Brambilla | Senior Vice President of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2025 | 8-K | Current Report |
| Nov 17, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 31, 2025 | 8-K | Current Report |
| Oct 22, 2025 | SCHEDULE 13G | Filing |
| Oct 2, 2025 | 8-K | Current Report |
| Sep 29, 2025 | 8-K | Current Report |
| Sep 29, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |